High Throughput Genomic Screening Preventive Healthcare Market

Whole genome sequencing is estimated at 41.0% of screening solutions in 2026, while hereditary disease screening accounts for 38.0% of clinical applications and hospitals and health systems hold 36.0% of end users. Adoption depends on clinically actionable interpretation, while consent, reimbursement and follow-up capacity limit program scale.